Johnsons & Johnsons to buy bio-tech company for $30 billion

Swiss biotech company Actelion said on Thursday it had agreed to be purchased by Johnson & Johnson in a $30 billion deal.


The all-cash offer, to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, was unanimously approved by the Boards of Directors of both companies, Actelion and Johnson & Johnson said in a joint statement.




Junior - Taleem Aam Karaingay - Juniors ko Parhaingay